

Is Eliquis in shortage in 2026? Get the latest update on Eliquis availability, pricing changes, new options, and how to find it in stock near you.
If you take Eliquis (Apixaban) to prevent strokes or treat blood clots, you may have heard talk of shortages or had trouble finding it at your pharmacy. With major pricing changes, supply chain shifts, and millions of patients depending on this medication, 2026 is a year of transition for Eliquis. Here's what's actually happening and what it means for you.
As of early 2026, Eliquis is not listed on the FDA or ASHP drug shortage lists. There is no formal manufacturing shortage. Bristol-Myers Squibb and Pfizer continue to produce and distribute both the 2.5 mg and 5 mg tablets.
That said, many patients are reporting difficulty finding Eliquis at their local pharmacies. This isn't a shortage in the traditional sense — it's a supply-demand imbalance at the pharmacy level. Some pharmacies run out between deliveries, especially in busy areas or at the beginning of the year when insurance plans reset.
Several factors are contributing to availability challenges in 2026:
Eliquis is the most prescribed anticoagulant in the United States. With an aging population and growing diagnoses of atrial fibrillation, demand continues to climb year over year. Individual pharmacies can't always keep up.
2026 marks the first year that negotiated Medicare prices take effect under the Inflation Reduction Act. Eliquis was one of the first 10 drugs selected. The new Medicare price dropped from about $521 to $231 per month. While this is a win for Medicare patients, the pricing transition is causing disruption across the supply chain as pharmacies, wholesalers, and PBMs adjust.
Despite FDA approval of several generic Apixaban manufacturers, generic Eliquis is not expected to launch until April 2028. Until then, there's only one product on the market — brand-name Eliquis. For more on why, see Why Is Eliquis So Hard to Find?
New year, new insurance rules. Some plans have changed their Eliquis coverage for 2026, requiring prior authorization or step therapy. This can cause prescription shifts and temporary demand spikes at certain pharmacies.
The cost of Eliquis varies significantly depending on your coverage:
For a full breakdown of savings options, read How to Save Money on Eliquis in 2026.
The biggest change in 2026 is the new Medicare negotiated price. If you're on Medicare Part D, your Eliquis costs should be significantly lower than in previous years. Combined with the $2,000 annual out-of-pocket cap, many Medicare patients will see real savings.
Bristol-Myers Squibb and Pfizer launched a direct-to-patient option through the Eliquis 360 Support Program. Cash-paying patients can get Eliquis shipped directly at more than 40% below the list price. This bypasses the retail pharmacy entirely. Call 855-354-7847 to learn more.
If you're uninsured or underinsured, the Bristol-Myers Squibb Patient Assistance Foundation may provide Eliquis for free. You can apply at bms.com or call 1-800-736-0003.
If your local pharmacy is out of Eliquis, here's what to do:
For more detailed strategies, see How to Find Eliquis in Stock Near You.
Eliquis is not in a formal shortage, but the combination of sky-high demand, Medicare pricing changes, and the absence of a generic means some patients will continue to face availability challenges in 2026. The situation should improve as the supply chain stabilizes and especially when generic Apixaban launches (expected April 2028).
In the meantime, plan ahead, use tools like Medfinder, and stay in touch with your doctor and pharmacist. If you're having trouble affording Eliquis, explore the savings programs available. And if you're considering switching medications, read our guide on Alternatives to Eliquis.
Most importantly: never stop taking Eliquis without talking to your doctor. The risk of stroke and blood clots increases when you discontinue this medication abruptly.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.